Core Insights - Smith+Nephew announces new evidence supporting the clinical performance of its REGENETEN Bioinductive Implant, aimed at treating rotator cuff tears and other tendon injuries [1][4] - The American Academy of Orthopaedic Surgeons (AAOS) has updated its Clinical Practice Guideline to highlight the benefits of bioinductive implants in rotator cuff repair, indicating lower re-tear rates and improved patient outcomes [2][5] - A randomized controlled trial (RCT) showed a 65% relative reduction in re-tear rates with the REGENETEN Implant compared to standard repair methods [4][6] Product Performance - The REGENETEN Bioinductive Implant has been used in over 150,000 procedures globally since its introduction in 2014, significantly impacting the treatment of tendon injuries [5][7] - Two-year re-tear rates were reported at 12.3% for the REGENETEN Implant versus 35.1% for standard repair, demonstrating its effectiveness [6][7] - The implant supports natural healing processes by facilitating the formation of new tissue, enhancing surgical repair outcomes [7][8] Market Expansion - Smith+Nephew is now able to market the REGENETEN Bioinductive Implant for extra-articular ligament injuries in the US, expanding its application beyond rotator cuff repairs [4][8] - Initial focus for this new indication will be on hip capsule repair, with potential for future expansions into other ligament repairs [4][8] Company Overview - Smith+Nephew is a global medical technology company focused on the repair, regeneration, and replacement of soft and hard tissue, with annual sales of $5.8 billion in 2024 [11] - The company operates in approximately 100 countries and employs around 17,000 people, dedicated to improving patient outcomes through innovative technologies [10][11]